EDUCATIONAL WEBINAR: Evidence-Based Strategy in the Prevention of Complications due to Retained Blood
An Educational Webinar with Presenters: Marc Gillinov, MD, Marc Gerdisch, MD, and Alyson Mehringer, RN discussing the basic principles of Chest Tube Management, the results of a 1 year quality improvement study and the operational perspective from the ICU Nursing Staff.
ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) was…
Elsloo, THE NETHERLANDS – September 28, 2016 — ClearFlow, Inc., a medical device company headquartered in Anaheim, California and with a European office in Amsterdam, has announced the opening of its new dedicated European Service Center near Maastricht, the Netherlands. ClearFlow is the maker of the PleuraFlow® Active Clearance Technology® System, which proactively prevents or minimizes chest tube clogging. A chest tube that is occluded can lead to…
ClearFlow Participates in Clinical Panel Presentations at Critical Care Conference Washington, DC – September 20, 2016—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the clinical and economic benefits of maintaining chest tube patency following cardiothoracic surgery last Friday at a session sponsored during the Cardiovascular-Thoracic (CVT) Critical Care Conference in Washington DC. Clinical cardiac surgery intensive care…
Anaheim, CA – July 26, 2016 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that its PleuraFlow® Active Clearance Technology® is now available for the treatment of pediatric cardiothoracic surgery patients. After receiving clearance from the United States Food & Drug Administration (FDA) earlier this year for expanded Indications for Use with the company’s patented technology, ClearFlow developed a new model of the…
Anaheim, CA – July 14, 2016—ClearFlow Inc., a medical device company based in Anaheim, California, has been named a finalist for this year’s Medical Marketing & Media (MM&M) Awards. MM&M, the premier business publication serving the healthcare industry for nearly 50 years, named ClearFlow’s interactive website among the five finalists in the category of Best Branded Website for Healthcare Professionals.’ Winners will be announced at the MM&M Awards…
–ClearFlow Technology Offers Solution– Anaheim, CA – June 28, 2016—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of another peer reviewed study in a leading cardiovascular surgery journal emphasizing the importance of preventing Retained Blood Syndrome (RBS). The Journal of Thoracic and Cardiovascular Surgery has published a peer-reviewed study from cardiac anesthesia and surgical investigators in Berlin detailing the heavy toll unevacuated…
–ClearFlow Hosts Panel of Thought Leaders in Montreal– Montreal, Canada — June 16, 2016 — A panel of distinguished heart surgeons from leading cardiac centers shared their experiences and strategies to optimize patient recovery after cardiothoracic surgery at a panel discussion in Montreal yesterday. Of emphasis was the ongoing challenge of high complication rates for patients who have inadequate postoperative blood evacuation, known as Retained Blood Syndrome (RBS),…
Anaheim, CA — (May 10, 2016) — ClearFlow, Inc., a California-based company that develops technology to maximize post-operative blood evacuation after cardiac surgery, has signed an agreement with Mayo Clinic in Rochester, MN for research on a Continuous Quality Improvement (CQI) program for patients recovering from heart surgery. Simon Maltais, M.D., Mayo Clinic Associate Professor, Division of Cardiovascular Surgery, is the Principal Investigator. Originally implemented in Japanese manufacturing…